AR056762A1 - (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos - Google Patents
(4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodosInfo
- Publication number
- AR056762A1 AR056762A1 ARP060104840A ARP060104840A AR056762A1 AR 056762 A1 AR056762 A1 AR 056762A1 AR P060104840 A ARP060104840 A AR P060104840A AR P060104840 A ARP060104840 A AR P060104840A AR 056762 A1 AR056762 A1 AR 056762A1
- Authority
- AR
- Argentina
- Prior art keywords
- forms
- pharmaceutically acceptable
- thrombosis
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente proporciona novedosos compuestos de sulfonilurea de formula (1) y sus derivados farmacéuticamente aceptables y formas polimorfas y amorfas. Los compuestos en sus diversas formas son inhibidores de los receptores de ADP plaquetarios eficaces y pueden utilizarse en diversas composiciones farmacéuticas, y son particularmente eficaces para la prevencion y/o tratamiento de enfermedades cardiovasculares, particularmente aquellas enfermedades relacionadas con la trombosis. También proporciona un método para preparar ese tipo de compuestos y formas y para prevenir o tratar la trombosis y afecciones relacionadas con la trombosis en un mamífero que comprende el paso de administrar una cantidad terapéuticamente eficaz de un compuesto de formula 1) o su sal o formas farmacéuticamente aceptables. Reivindicacion 1: Un compuesto que tiene la siguiente formula (1) donde: X se selecciona entre el grupo que consiste de F e I; R1 se selecciona entre el grupo que consiste en H, halogeno, -OH, alquilo C1-10 y alquilamino C1-6 o su derivado farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73365005P | 2005-11-03 | 2005-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056762A1 true AR056762A1 (es) | 2007-10-24 |
Family
ID=38023842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104840A AR056762A1 (es) | 2005-11-03 | 2006-11-03 | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos |
Country Status (21)
Country | Link |
---|---|
US (3) | US20070208045A1 (es) |
EP (2) | EP1951254B1 (es) |
JP (1) | JP5509406B2 (es) |
KR (1) | KR101423483B1 (es) |
CN (1) | CN101300013B (es) |
AR (1) | AR056762A1 (es) |
AT (1) | ATE540034T1 (es) |
AU (1) | AU2006311795B2 (es) |
BR (1) | BRPI0618210A2 (es) |
CA (1) | CA2627719C (es) |
CY (1) | CY1112826T1 (es) |
DK (1) | DK1951254T3 (es) |
EA (1) | EA017402B1 (es) |
ES (1) | ES2380814T3 (es) |
HK (1) | HK1121051A1 (es) |
IL (1) | IL191193A (es) |
NZ (2) | NZ596025A (es) |
PT (1) | PT1951254E (es) |
TW (2) | TWI397529B (es) |
WO (2) | WO2007056167A2 (es) |
ZA (1) | ZA200804241B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006002099A2 (en) | 2004-06-18 | 2006-01-05 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
ES2380814T3 (es) * | 2005-11-03 | 2012-05-18 | Portola Pharmaceuticals, Inc. | [4-(6-HALO-7-sustituidas-2,4-DIOXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)-FENIL]-5-CLORO-TIOFEN-2-IL-SULFONILUREAS y formas y métodos relacionados con las mismas |
MX2008014193A (es) | 2006-05-05 | 2009-03-31 | Millennium Pharm Inc | Inhibidores del factor xa. |
EP2138482A4 (en) | 2007-04-19 | 2011-06-15 | Astellas Pharma Inc | BICYCLIC HETEROCYCLIC COMPOUND |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
CN101795682A (zh) | 2007-05-02 | 2010-08-04 | 波托拉医药品公司 | 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 |
EP2146705B1 (en) * | 2007-05-02 | 2014-03-05 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
CN101679358B (zh) * | 2007-06-18 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的吡咯衍生物 |
CN101654441B (zh) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
KR20110097829A (ko) * | 2008-11-14 | 2011-08-31 | 포톨라 파마슈티컬스, 인코포레이티드 | 낮은 pH에서 불량한 수용해도를 갖는 이온화가능한 활성제의 제어 방출을 위한 고체 조성물, 및 그의 사용 방법 |
WO2011006169A1 (en) | 2009-07-10 | 2011-01-13 | Portola Pharmaceuticals, Inc. | Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2 |
US8729095B2 (en) | 2009-08-28 | 2014-05-20 | Daiichi Sankyo Company, Limited | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases |
CN102762550B (zh) | 2009-12-17 | 2015-04-01 | 米伦纽姆医药公司 | Xa因子抑制剂的盐和结晶形式 |
WO2011075602A1 (en) | 2009-12-17 | 2011-06-23 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
EP2523657A1 (en) | 2010-01-12 | 2012-11-21 | Portola Pharmaceuticals, Inc. | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
WO2011137459A1 (en) | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
CN103339126B (zh) * | 2010-12-03 | 2016-06-29 | 博尔托拉制药公司 | 式(i)化合物的固态形式及其药物组合物、剂型和使用方法 |
JP6268093B2 (ja) * | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
RU2556198C1 (ru) * | 2014-04-10 | 2015-07-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию |
US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE845042C (de) | 1950-07-14 | 1952-07-28 | Basf Ag | Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden |
US3847925A (en) * | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
DE3134780A1 (de) * | 1981-09-02 | 1983-03-10 | Hoechst Ag, 6000 Frankfurt | "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung" |
US4720450A (en) * | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
AU6395094A (en) | 1993-03-15 | 1994-10-11 | G.D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
TW448161B (en) | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
JPH0881442A (ja) | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
US6413724B1 (en) * | 1996-10-28 | 2002-07-02 | Versicor, Inc. | Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones |
US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
JPH10195323A (ja) | 1997-01-09 | 1998-07-28 | Nippon Paper Ind Co Ltd | 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体 |
SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
WO1999036425A1 (en) | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
JP2000204081A (ja) | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
CA2400479C (en) | 2000-02-04 | 2010-10-05 | Millennium Pharmaceuticals, Inc. | Platelet adp receptor inhibitors |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
EP1330444B1 (en) * | 2000-11-01 | 2011-03-23 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic compounds and process for making them |
JP2005523249A (ja) * | 2002-01-09 | 2005-08-04 | エンズレル インコーポレイテッド | 多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達 |
US20040242658A1 (en) * | 2003-01-08 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Amorphous form of rosiglitazone maleate and process for preparation thereof |
ATE448222T1 (de) * | 2003-10-03 | 2009-11-15 | Portola Pharm Inc | 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe |
ES2380814T3 (es) * | 2005-11-03 | 2012-05-18 | Portola Pharmaceuticals, Inc. | [4-(6-HALO-7-sustituidas-2,4-DIOXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)-FENIL]-5-CLORO-TIOFEN-2-IL-SULFONILUREAS y formas y métodos relacionados con las mismas |
CN101795682A (zh) * | 2007-05-02 | 2010-08-04 | 波托拉医药品公司 | 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 |
CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
-
2006
- 2006-11-03 ES ES06827506T patent/ES2380814T3/es active Active
- 2006-11-03 US US11/556,518 patent/US20070208045A1/en not_active Abandoned
- 2006-11-03 EP EP06827506A patent/EP1951254B1/en active Active
- 2006-11-03 EA EA200801245A patent/EA017402B1/ru not_active IP Right Cessation
- 2006-11-03 NZ NZ596025A patent/NZ596025A/xx not_active IP Right Cessation
- 2006-11-03 PT PT06827506T patent/PT1951254E/pt unknown
- 2006-11-03 ZA ZA200804241A patent/ZA200804241B/xx unknown
- 2006-11-03 US US11/556,490 patent/US8058284B2/en active Active
- 2006-11-03 CN CN2006800410635A patent/CN101300013B/zh not_active Expired - Fee Related
- 2006-11-03 AT AT06827506T patent/ATE540034T1/de active
- 2006-11-03 WO PCT/US2006/042998 patent/WO2007056167A2/en active Application Filing
- 2006-11-03 CA CA2627719A patent/CA2627719C/en not_active Expired - Fee Related
- 2006-11-03 AR ARP060104840A patent/AR056762A1/es unknown
- 2006-11-03 JP JP2008539089A patent/JP5509406B2/ja active Active
- 2006-11-03 WO PCT/US2006/043093 patent/WO2007056219A2/en active Application Filing
- 2006-11-03 BR BRPI0618210-0A patent/BRPI0618210A2/pt not_active Application Discontinuation
- 2006-11-03 NZ NZ567747A patent/NZ567747A/en not_active IP Right Cessation
- 2006-11-03 EP EP11176014A patent/EP2428514A1/en not_active Withdrawn
- 2006-11-03 KR KR1020087013178A patent/KR101423483B1/ko active IP Right Grant
- 2006-11-03 TW TW095140753A patent/TWI397529B/zh not_active IP Right Cessation
- 2006-11-03 AU AU2006311795A patent/AU2006311795B2/en not_active Ceased
- 2006-11-03 TW TW095140749A patent/TW200728260A/zh unknown
- 2006-11-03 DK DK06827506.4T patent/DK1951254T3/da active
-
2008
- 2008-05-01 IL IL191193A patent/IL191193A/en not_active IP Right Cessation
-
2009
- 2009-01-13 HK HK09100322.0A patent/HK1121051A1/xx not_active IP Right Cessation
-
2011
- 2011-10-11 US US13/271,037 patent/US20120088736A1/en not_active Abandoned
-
2012
- 2012-04-04 CY CY20121100393T patent/CY1112826T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
DOP2007000079A (es) | Compuestos fenil amido heterocíclicos condensados | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
DK1257550T3 (da) | Blodplade-ADP-receptor-inhibitor | |
UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
AR053415A1 (es) | Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion | |
AR051780A1 (es) | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos | |
PE20090219A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
AR034556A1 (es) | Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20050325A1 (es) | DERIVADOS DE PIRROLO[3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
AR053435A1 (es) | Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3. | |
EA200901474A1 (ru) | Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе | |
AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. | |
PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
UY26564A1 (es) | Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos | |
ATE469157T1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
AR058329A1 (es) | Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica | |
AR016644A1 (es) | Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos | |
EA200501148A1 (ru) | Пиридилоксиметильные и бензизоксазольные азабициклические производные |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |